ESMO Congress
ESMO Congress takes place on 17–21 September 2027 at Fira Gran Via, Barcelona. It is organised by European Society for Medical Oncology (ESMO), and B2DB lists 252 speakers and 165 sessions announced so far.
The ESMO Congress 2027 will take place from 17 to 21 September 2027 in Barcelona, Spain, with sessions also available through a dedicated virtual platform. The Congress brings together oncology professionals, patient advocates, journalists and healthcare industry representatives to explore advances in oncology and their implications for patient care. The scientific and educational programme spans basic, translational and clinical research, with topics including cancer prevention, diagnostics, therapeutic strategies and the role of artificial intelligence.
Key facts
| Dates | 17–21 September 2027 (upcoming) |
|---|---|
| Venue | Fira Gran Via, Barcelona, Spain |
| Organiser | European Society for Medical Oncology (ESMO) |
| Series | ESMO Congress |
| Speakers | 252 |
| Sessions | 165 |
| Stages | Leon Auditorium - Hall 6, Malaga Auditorium - Hall 3, Murcia Auditorium - Hall 3, Granada Auditorium - Hall 6, Pamplona Auditorium - Hall 5, Cordoba Auditorium - Hall 6, Salamanca Auditorium - Hall 5, Santander Auditorium - Hall 5, Oviedo Auditorium - Hall 5, Alicante Auditorium - Hall 4, Madrid Auditorium - Hall 6, Burgos Auditorium - Hall 2, Cadiz Auditorium - Hall 2, Almeria Auditorium - Hall 2, Bilbao Auditorium - Hall 2, Barcelona Auditorium - Hall 2 |
| Official site | esmo.org/meeting-calendar/esmo-congress-2027/programme |
Keynote speakers
- Johann S. De Bono Royal Marsden Hospital Institute of Cancer Research
Who is speaking at ESMO Congress?
252 speakers. Compiled from the published agenda; speakers can claim and verify their own entry.
- Johann S. De Bono Royal Marsden Hospital Institute of Cancer Research
- Marjolein Geurts Associate Professor (UHD), Erasmus MC
- Lorenza Rimassa Head, Hepatopancreatobiliary Oncology Unit, Humanitas
- Christina H. Ruhlmann Associate Professor, MD, PhD, OUH Odense Universitetshospital
- Hui Gan Director of Cancer Clinical Trials, Austin Health
- Antonio Passaro Direttore, Divisione UOC Oncologia Toracia, IEO Istituto Europeo di Oncologia
- Hope S. Rugo Professor, City of Hope Comprehensive Cancer Center
- Alessandro Aiuti Deputy Director, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
- Marcela Maus Director of Cellular Immunotherapy, MGH Cancer Center; Professor, Massachusetts General Hospital
- Raffaella Casolino Medical-Scientific Policy Advisor, European Society for Medical Oncology (ESMO)
- Hanneke Van Laarhoven Professor, Head of the Department of Medical Oncology, Amsterdam UMC
- Leila Amini Qualified Person, Charité – Universitätsmedizin Berlin
- Pablo Nenclares Consultant Clinical Oncologist, Barts Health NHS Trust
- Martin Hutchings Senior Consultant, Rigshospitalet
- Roberta Sanfilippo Medical Director, IEO Istituto Europeo di Oncologia
- Andrea De Censi Director Breast Department, Champalimaud Foundation
- Judy E. Garber Director, Cancer Genetics and Prevention, Dana-Farber Cancer Institute
- Elisa Fontana Sarah Cannon Research Institute SCRI UK
- Jacqueline T. Brown Assistant Professor, Winship Cancer Institute of Emory University
- Christopher J Sweeney University of Adelaide
- Solange Peters CHUV - Centre Hospitalier Universitaire Vaudois
- Hemant Malhotra MGMCH - Mahatma Gandhi Medical College & Hospital
- Manuela Schmidinger MedUni Wien - Medical University of Vienna
- Alexander M. Menzies Melanoma Institute Australia
- Aisha Miah The Royal Marsden Hospital - Chelsea
- Alistair Ring
- Angelica N. Rodrigues Faculdade de Medicina da UFMG
- Arjan Diepstra UMCG - University Medical Center Groningen
- Carlos H. Barrios
- Christina Yap ICR - The Institute of Cancer Research - North Site
- Christoph Zielinski
- Clara Montagut
- Clarissa Maria De Cerqueira Mathias NOB - Nucleo de Oncologia da Bahia - Grupo Oncoclinicas
- Claudia Waskow Jena University Hospital, Friedrich-Schiller
- Dominik Paul Modest
- Emile E. Voest NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital
- Erika B. Ruiz-García INCAN - Instituto Nacional de Cancerologia
- Grigorios A. Kaltsas National & Kapodistrian University of Athens (NKUA)
- Guillermo Argiles Martinez MSKCC - Memorial Sloan Kettering Cancer Center
- Ines Vaz-Luis
- Isabelle L. Ray-Coquard
- Javier C. Cortés IBCC - International Breast Cancer Center
- Jaydira Del Rivero NIH - National Institutes of Health
- John B. Haanen NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital
- Kathleen N. Moore Fred And Pamela Buffett Cancer Center At The University Of Nebraska Medical Center
- Kevin J. Harrington Royal Marsden Hospital Institute of Cancer Research
- Mererid Evans UHW - University Hospital of Wales
- Michiel S. Van der Heijden
- Miguel Quintela-Fandino
- Nicholas A. Watkin St George's Hospital
- Noemi Reguart
- Petra Reinke
- Ralf Dieter Hofheinz UMM - Universitaetsklinikum Mannheim
- Rodrigo Sanchez Bayona Hospital Universitario 12 de Octubre
- Samantha O. Hasenleithner Medical University of Graz
- Sandra Misale Johns Hopkins University - School of Medicine
- Sandra Strauss University College London Hospitals NHS Foundation Trust
- Stephen V. Liu Lombardi Cancer Center Georgetown University
- Sven Borchmann Universitätsklinikum Köln (AöR)
- Thomas Newsom-Davis
- Tim Cooksley The Christie NHS Foundation Trust
- Yinxiu Zhan
- Ravindran Kanesvaran Deputy Chair and Senior Consultant, NCCS - National Cancer Centre Singapore
- Maria Alice Franzoi Medical Oncologist / Researcher, Gustave Roussy
- Julien Vibert Postdoctoral Research Fellow, NCT Heidelberg - National Center for Tumor Diseases (NCT) Heidelberg
- Lillian L. Siu Medical Oncologist, Princess Margaret Cancer Centre
- Filippo Pietrantonio Medical Oncologist, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
- Anne Letsch Head Cancer Center (Onkologisches Zentrum) UKSH Campus Kiel, Universitätsklinikum Schleswig-Holstein
- Christian Grommes Neurologist; Neuro-oncologist, Memorial Sloan Kettering Cancer Center
- Jayesh Desai Associate Director Clinical Research, Peter MacCallum Cancer Centre
- Sophia Yien Ning Wong Consultant, National Cancer Centre Singapore
- Suzette Delaloge Oncologue médical, Praticien Spécialiste des CLCC, Gustave Roussy
- Karl-Johan Malmberg Professor, Universitetet i Oslo (UiO)
- Gabriella Pravettoni Director of the Department of Oncology and Hemato-oncology (DIPO), Università degli Studi di Milano
- Jason Westin Service Line Executive Leadership - Lymphoma & Myeloma, UT MD Anderson
- Marzia Del Re Freelancer, IDI IRCCS - Istituto Dermopatico dell'Immacolata
- Amanda Psyrri Chairman of Internal Medicine, Β' Προπαιδευτική Παθολογική Κλινική (ΕΚΠΑ) - ΠΓΝ "Αττικόν"
- Aparna Parikh Chief Scientist, Reversing Early Recurrence
- Camilla Zimmermann Director of Palliative Care, University Health Network
- Corinne Faivre-Finn Professor of Thoracic Radiation Oncology, University of Manchester
- Hans Gelderblom Prof Medical Oncology, Department Chair, Leiden University Medical Center
- Helena Linardou Director, 4th Oncology Dept & Clinical Trials Center, Metropolitan Hospital
- Mario Mandalà Full Professor, Università degli Studi di Perugia
- Christof Vulsteke Medical Oncologist, AZ Maria Middelares
- Rodrigo Dienstmann Group Lead, Vall d'Hebron Institute of Oncology (VHIO)
- Désirée Deandreis Chef de Service, Service de Médecine Nucléaire, Gustave Roussy
- Andrea Riccardo Filippi Head of Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
- Yardena Samuels Director, Moross Integrated Cancer Center, Weizmann Institute of Science
- Nicolas Girard Chair, Department of Medical Oncology, Institut Curie
- Francesca Spada Coordinatore Delle LG AIOM per le Neoplasie Neuroendocrine, IEO Istituto Europeo di Oncologia
- Ingrid Glimelius Professor - Oncology, Uppsala University
- David Barbie Professor, Dana-Farber Cancer Institute
- Alona Zer Clinical Associate Professor, Technion - Israel Institute of Technology
- Anna Koumarianou Consultant in Medical Oncology, Attikon University General Hospital
- Isacco Montroni Chief of Colon and Rectal Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
- Clare A. Turnbull Professor in Translational Cancer Genetics, Institute of Cancer Research
- Roger Olofsson Bagge Professor, University of Gothenburg
- Tessa Brabander Radiologist, Erasmus MC
- Simon Oberst Director of Quality and Accreditation, OECI (Organisation of European Cancer Institutes)
- Scott Bratman Full Professor, University of Toronto
- Andri Papakonstantinou Postdoctoral Fellow, Karolinska institutet
- Herbert Ho Fung Loong The Chinese University of Hong Kong - Prince of Wales Hospital
- Leonor Cerdá-Alberich Health Research Institute Hospital La Fe
- Jessica J. Lin Program Director, Thoracic Medical Oncology, Massachusetts General Hospital
- Sacha J. Howell Professor of Medical Oncology, University of Manchester
- Laura A. Huppert UCSF - University of California San Francisco
- Ashleigh Guadagnolo Chief Medical Officer-ad Interim, Physician Referal Service (MD Anderson Practice Plan), UT MD Anderson
- Jean-Pascal Machiels Directeur Médical, Cliniques universitaires Saint-Luc
- Ryan J. Sullivan Chief Financial Officer, Lynn Community Health Center
- Patrizia Giannatempo Medical Oncologist, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
- Inga-Marie Schaefer Affiliate Faculty, Department of Pathology, Mass General Brigham
- Irit Ben-Aharon Senior Vice Dean, Faculty of Medicine Technion
- Alice Bernard-Tessier Postdoctoral Researcher, Dana-Farber Cancer Institute
- Margot Tesselaar Internist Oncoloog, Antoni van Leeuwenhoek
- Evanthia Galanis Mayo Clinic, Rochester, USA
- Mauro Cives Associate Professor, Università degli Studi di Bari
- Scott M. Haake Assistant Professor, Vanderbilt University Medical Center
- Daniel Shao Weng Tan NCCS - National Cancer Centre Singapore
- Stephen L. Chan The Chinese University of Hong Kong - Prince of Wales Hospital
- Carol Fabian Professor of Medicine, University of Kansas Medical Center
- Do-Youn Oh Seoul National University Hospital
- Myung-Ju Ahn Hanyang University College of Medicine
- Karine Martins Da Trindade Gerente Médica do Instituto D'Or de Ensino e Pesquisa CE / Manager of IDOR CE, Instituto D'Or de Pesquisa e Ensino
- Alia Munir Consultant Physician, Sheffield Teaching Hospitals NHS Foundation Trust
- Kohei Shitara National Cancer Center Hospital East
- Pei Li Stephanie Saw NCCS - National Cancer Centre Singapore
- Simon Husby Læge, PhD, Rigshospitalet
- Aya El-Helali HKU - The University of Hong Kong
- Ben Solomon Peter MacCallum Cancer Center
- Elena Castro Marcos Hospital Universitario 12 de Octubre
- Andrew S. Epstein Medical Oncologist, Memorial Sloan Kettering Cancer Center
- Daniel Truhn Uniklinik RWTH Aachen - Institut für Diagnostische und Interventionelle Radiologie
- Brigette B. Ma The Chinese University of Hong Kong - Sino Building
- Lu Xie Peking University People's Hospital
- Yi-Long Wu Guangdong Province People's
- Guillaume Jaume UNIL - University of Lausanne
- Lisa Zimmer Universitätsklinikum Essen (AöR)
- Felix Sahm F., Universitätsklinikum Heidelberg
- Ines E. Pires da Silva Fundação Champalimaud
- Jian Zhang Fudan University Shanghai Cancer Center
- Marion Subklewe LMU Klinikum der Universität München
- Winette T. Van der Graaf NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital
- Alexander Lyon Imperial College London - Hammersmith Campus
- Ana C. Garrido-Castro Dana Farber Cancer Institute
- Ana Maria Arance Hospital Clinic y Provincial de Barcelona
- Ana Oaknin Hospital Universitario Puerta de Hierro Majadahonda
- Andrew Aguirre Dana-Farber Cancer Institute
- Andrew Furness The Royal Marsden Hospital - Chelsea
- Anna Sophie Berghoff MedUni Wien - Medical University of Vienna
- Anssi Auvinen University of Tampere
- Beate Rau Charité-Universitaetsmedizin Berlin - Campus Virchow Klinikum (CVK)
- Benjamin Haibe-Kains UHN - University Health Network - Princess Margaret Cancer Centre
- Bettina Ryll Melanoma Patient Network Europe MPNE
- Bhumsuk Keam Seoul National University Hospital
- Changsong Qi Peking University Cancer Hospital & Institute
- Christian K. Kollmannsberger BC Cancer Agency - Vancouver
- Christoph Benedikt Westphalen LMU Klinikum der Universität München
- Christophe M. Deroose UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg
- Cindy Neuzillet Hopital Ambroise Pare AP-HP
- Claire Gallois HEGP - Hopital Europeen Georges-Pompidou - AP-HP
- Colin Lindsay The Christie NHS Foundation Trust
- Cristina Saura Manich Vall d'Hebron University Hospital
- Daniel Peeper Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL)
- David F. McDermott Oncology, Beth Israel Deaconess Medical Center
- David Hui The University of Texas MD Anderson Cancer Center
- David P. Miller Wake Forest University School of Medicine
- Detlef K. Bartsch Philipps-University Marburg
- Eduardo Vilar The University of Texas M. D. Anderson Cancer Center
- Elaine Shum New York University Medical Center
- Elizabeth A. Connolly Peter MacCallum Cancer Centre
- Erica Pietroluongo Università degli Studi di Napoli Federico II
- Etienne G. Brain Hopital René Huguenin - Institut Curie
- Fernando C. Maluf Hospital Beneficencia Portuguesa of Sao Paulo
- Francesco Panzuto Doctor, Azienda ospedaliero-universitaria Sant'Andrea
- Frederik Marmé Heidelberg University - Faculty of Medicine in Mannheim
- Fredrik Strand Karolinska University Hospital and Karolinska Institute - Huddinge
- Gabriel G. Malouf Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)
- Gloria Iacoboni VHIO - Vall d'Hebron Institute of Oncology
- Hildur Helgadottir Karolinska Institutet - Cancer Center Karolinska (CCK)
- Iain McNeish Imperial College London - Hammersmith Hospital
- Ikram Eseghir NABD-BC2 Association
- Inge Marie Svane Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK)
- Irene G. Braña Vall d'Hebron University Hospital
- Isaac Garcia-Murillas ICR - Institute of Cancer Research - Chester Beatty Laboratories
- James Gulley National Cancer Institute
- Javier Martin-Broto Hospital Universitario Fundacion Jimenez Diaz
- Jean-Yves Blay Centre Léon Bérard
- Jeanine Roodhart UMC - University Medical Center Utrecht
- Jeremie Calais UCLA - David Geffen School of Medicine
- Josep Tabernero Vall d'Hebron University Hospital
- Joyce F. Liu Oncology, Dana-Farber Cancer Institute
- Juan Manuel Ramon O'Connor Instituto Alexander Fleming
- Juan Manuel Sepulveda Sanchez Hospital Universitario 12 de Octubre
- Julia Murray Royal Marsden Hospital Institute of Cancer Research
- Julien Edeline Centre Eugene - Marquis
- Kevin Punie ZAS - Ziekenhuis aan de Stroom
- Kim Nguyen Chi BC Cancer Agency - Vancouver
- Komal Jhaveri Memorial Sloan Kettering Evelyn H. Lauder Breast Center
- Laura D. Locati Fondazione IRCCS - Istituto Nazionale dei Tumori
- Louis De Mestier Beaujon Hospital APHP
- Lucie Heinzerling Servier Deutschland GmbH
- Luis Paz-Ares Hospital Universitario 12 de Octubre
- Mairead G. McNamara The Christie NHS Foundation Trust
- Maribel Del Olmo Hospital Universitario y Politécnico la Fe de Valencia
- Marija Balic University of Pittsburgh Medical Center Hillman Cancer Cente
- Marion Van Mackelenbergh UKSH - Universitätsklinikum Schleswig-Holstein - Campus Kiel
- Martina Sollini UniSR - Università Vita e Salute San Raffaele Milano
- Melissa B. Davis Weill Cornell Medicine
- Michael Alvarado UCSF Helen Diller Family Comprehensive Cancer Center
- Michael Jefford Peter MacCallum Cancer Center
- Michelino De Laurentiis Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
- Nadia Haj Mohammad UMC - University Medical Center Utrecht
- Nancy Lee MSKCC - Memorial Sloan Kettering Cancer Center
- Nathaniel Treister Brigham and Women's Hospital
- Naureen Starling The Royal Marsden Hospital - Chelsea
- Nicos Fotiadis The Royal Marsden Hospital - Chelsea
- Nikolaj Frost Charité-Universitaetsmedizin Berlin - Campus Virchow Klinikum (CVK)
- Olivier A. Michielin HUG - Hopitaux Universitaires de Geneve
- Olivier Scatton Hopital Pitié Salpetrière AP-HP
- Panagiota Oikonomopoulou Attikon University Hospital
- Paola Alberti Università degli Studi di Milano Bicocca - Facoltà di Medicina e Chirurgia
- Paul A. Harris Vanderbilt University Medical Center
- Rafal Dziadziuszko Medical University of Gdansk
- Raghav Sundar Yale School of Medicine
- Raphael S. Werner USZ - University Hospital Zürich
- Rebecca A. Gladdy Princess Margaret Cancer Centre
- Roberto Carmagnani Pestana Hospital Israelita Albert Einstein (Morumbi) - Pavilhao Vicky e Joseph Safra
- Roberto Ferrara UniSR - Università Vita e Salute San Raffaele Milano
- Roisin E. O'Cearbhaill Memorial Sloan Kettering Evelyn H. Lauder Breast Center
- Ruth Langley UCL - University College London
- Sapna P. Patel University of Colorado Denver - Anschutz Medical Campus
- Sara A. Hurvitz University of Washington
- Sebastien Moine The University of Edinburgh
- Silvia Stacchiotti Fondazione IRCCS - Istituto Nazionale dei Tumori
- Simron Singh Odette Cancer Centre - Sunnybrook Health Sciences Centre
- Sirpa Leppä University of Helsinki
- Sjoukje Oosting UMCG - University Medical Center Groningen
- Sumanta K. Pal City of Hope Comprehensive Cancer Center
- Teresa Macarulla Mercade Hospital Clinic y Provincial de Barcelona
- Toshirou Nishida JCHO Osaka Hospital (formerly Osaka Kosei Nenkin Hospital)
- Trevor Pugh UHN - University Health Network - Princess Margaret Cancer Centre
- Valentina Guarneri Università degli Studi di Padova
- Valter Longo USC - Institute for Global Health
- Vedang Murthy ACTREC Tata Memorial Centre
- Veronique C. Dieras Centre Eugene - Marquis
- Volkmar Mueller University Hospital Hamburg-Eppendorf
- Winta Mehtsun University of California, San Diego Health
- Xavier Paoletti Institut Curie
- Xiaojie Bian Fudan University Shanghai Cancer Center
- Yeon Hee Park Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine
- Yohann Loriot Doctor, Gustave Roussy
- Zev A. Wainberg UCLA - David Geffen School of Medicine
Most represented companies
- Dana-Farber Cancer Institute — 5 speakers
- Gustave Roussy — 4 speakers
- Hospital Universitario 12 de Octubre — 4 speakers
- The Royal Marsden Hospital - Chelsea — 4 speakers
- IEO Istituto Europeo di Oncologia — 3 speakers
- NCCS - National Cancer Centre Singapore — 3 speakers
- NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital — 3 speakers
- Royal Marsden Hospital Institute of Cancer Research — 3 speakers
- The Christie NHS Foundation Trust — 3 speakers
- Vall d'Hebron University Hospital — 3 speakers
What's on the agenda at ESMO Congress?
165 sessions.
Day 1 — Friday 17 September 2027
- Industry Satellite 3 09:45–11:15 · Leon Auditorium - Hall 6
- Industry Satellite 4 09:45–11:15 · Malaga Auditorium - Hall 3
- Industry Satellite 5 09:45–11:15 · Murcia Auditorium - Hall 3
- Industry Satellite 2 09:45–11:15 · Granada Auditorium - Hall 6
- Industry Satellite 7 09:45–11:15 · Pamplona Auditorium - Hall 5
- Industry Satellite 1 09:45–11:15 · Cordoba Auditorium - Hall 6
- Industry Satellite 8 09:45–11:15 · Salamanca Auditorium - Hall 5
- Industry Satellite 9 09:45–11:15 · Santander Auditorium - Hall 5
- Industry Satellite 6 09:45–11:15 · Oviedo Auditorium - Hall 5
- Opening session 11:30–13:00 · Alicante Auditorium - Hall 4
- New wave of drug development 13:30–15:00 · Madrid Auditorium - Hall 6 — Daniel Shao Weng Tan, Christophe M. Deroose, James Gulley
- Managing menopausal symptoms in women with breast cancer or at high risk of breast cancer 13:30–14:15 · Oviedo Auditorium - Hall 5 — Carol Fabian
- What’s new in colorectal cancer: Targets, drugs, interventional technologies 13:30–15:00 · Burgos Auditorium - Hall 2 — Clara Montagut, Guillermo Argiles Martinez, Naureen Starling, Olivier Scatton
- Tumor-agnostic drug development: Perspectives from academia, industry, regulators, payors and patients 13:30–15:00 · Salamanca Auditorium - Hall 5 — Emile E. Voest, Bettina Ryll
- Centralisation of care for cancers that need an expert team for better outcomes 13:30–15:00 · Santander Auditorium - Hall 5 — Simon Oberst, Andri Papakonstantinou, Jean-Yves Blay
- Optimising treatment sequencing in locally advanced head and neck cancer 13:30–15:00 · Malaga Auditorium - Hall 3 — Pablo Nenclares, Amanda Psyrri, Brigette B. Ma, Sjoukje Oosting
- How exercise and diet modulate tumor metabolism and therapy response 13:30–15:00 · Leon Auditorium - Hall 6 — Sumanta K. Pal, Valter Longo
- Loco-regional hepatobiliary cancers (HCC) and biliary tract cancer (BTC): Current standards, emerging strategies, and unmet needs 13:30–15:00 · Cadiz Auditorium - Hall 2 — Lorenza Rimassa, Stephen L. Chan, Julien Edeline
- Keynote lecture 1 15:15–15:45 · Almeria Auditorium - Hall 2
- From toxicity to decisions in early oncology trials: Integrating clinical insight, patient experience, and methodological innovation 16:15–17:45 · Cordoba Auditorium - Hall 6 — Christina Yap, Jayesh Desai, Xavier Paoletti
- Cancer prevention therapeutics: What is emerging, what is actionable 16:15–17:45 · Santander Auditorium - Hall 5 — Andrea De Censi, Eduardo Vilar, Ruth Langley
- Real-world and late stage clinical trial experience with cell therapies 16:15–17:45 · Madrid Auditorium - Hall 6 — Alessandro Aiuti
- Oligometastatic STS: Time to put surgery and SBRT on trial 16:15–17:30 · Malaga Auditorium - Hall 3 — Ashleigh Guadagnolo, Elizabeth A. Connolly, Nicos Fotiadis, Rebecca A. Gladdy +1 more
- Melanoma as a blueprint: New actors in immune checkpoint inhibitor (ICI) resistance 16:15–17:45 · Leon Auditorium - Hall 6 — Ryan J. Sullivan, Lisa Zimmer, Ana Maria Arance, Andrew Furness
- Management HER2+ metastatic disease 16:15–17:30 · Burgos Auditorium - Hall 2 — Rodrigo Sanchez Bayona, Yeon Hee Park
- HPV-related oropharyngeal cancer: Beyond de-escalation 16:15–17:00 · Oviedo Auditorium - Hall 5 — Mererid Evans, Nancy Lee
- Living with and beyond advanced cancer: Should we redefine survivorship? 16:15–17:00 · Pamplona Auditorium - Hall 5 — Christina H. Ruhlmann, Michael Jefford
- Is there a role for local radiotherapy in the management of metastatic NSCLC? 16:15–17:00 · Granada Auditorium - Hall 6 — Corinne Faivre-Finn
- Industry Satellite 12 18:15–19:45 · Leon Auditorium - Hall 6
- Industry Satellite 13 18:15–19:45 · Malaga Auditorium - Hall 3
- Industry Satellite 14 18:15–19:45 · Murcia Auditorium - Hall 3
- Industry Satellite 15 18:15–19:45 · Oviedo Auditorium - Hall 5
- Industry Satellite 17 18:15–19:45 · Salamanca Auditorium - Hall 5
- Industry Satellite 16 18:15–19:45 · Pamplona Auditorium - Hall 5
- Industry Satellite 18 18:15–19:45 · Santander Auditorium - Hall 5
- Industry Satellite 10 18:15–19:45 · Cordoba Auditorium - Hall 6
- Industry Satellite 11 18:15–19:45 · Granada Auditorium - Hall 6
Day 2 — Saturday 18 September 2027
- New predictive biomarkers beyond gene expression 08:30–09:15 · Cadiz Auditorium - Hall 2 — Javier C. Cortés
- What agentic AI means for oncology decision-making 08:30–10:00 · Bilbao Auditorium - Hall 2 — Yinxiu Zhan, Leonor Cerdá-Alberich, Daniel Truhn, Guillaume Jaume +1 more
- Emerging treatments options in advanced pancreatic cancer 08:30–10:00 · Almeria Auditorium - Hall 2 — Andrew S. Epstein, Cindy Neuzillet, Teresa Macarulla Mercade, Zev A. Wainberg
- Early-onset colorectal cancer: Cancer is only part of the equation 08:30–09:15 · Leon Auditorium - Hall 6 — Elisa Fontana, Irit Ben-Aharon
- Targeted therapies for CNS cancer: From biology to clinical practice 08:30–10:00 · Salamanca Auditorium - Hall 5 — Christian Grommes, Juan Manuel Sepulveda Sanchez
- When therapies collide: Managing toxicities of combination therapies 08:30–10:00 · Cordoba Auditorium - Hall 6 — Tim Cooksley, Nathaniel Treister, Paola Alberti
- Manufacturing of cell therapies: Centers of excellence for advanced therapy 08:30–10:00 · Oviedo Auditorium - Hall 5 — Petra Reinke, Sophia Yien Ning Wong
- Management of patients with high-risk localised and locally advanced prostate cancer 08:30–10:00 · Barcelona Auditorium - Hall 2 — Christopher J Sweeney, Jeremie Calais, Julia Murray
- Governing the next wave of innovation in oncology: Genomics, data, and AI 10:15–11:45 · Santander Auditorium - Hall 5 — Raffaella Casolino, Christoph Zielinski, Ikram Eseghir, Melissa B. Davis
- New developments in oncogene-addicted NSCLC 10:15–11:45 · Barcelona Auditorium - Hall 2 — Antonio Passaro, Jessica J. Lin, Pei Li Stephanie Saw, Colin Lindsay
- Update on use of biomarkers to inform advanced prostate cancer management 10:15–11:45 · Granada Auditorium - Hall 6 — Elena Castro Marcos
- The next frontier in gynaecological cancers: Cell cycle targets, immune engagers and advanced ADCs 10:15–11:45 · Bilbao Auditorium - Hall 2 — Isabelle L. Ray-Coquard, Ana Oaknin, Iain McNeish, Roisin E. O'Cearbhaill
- Controversies in the application of ctDNA for the management of breast cancer in early and late stage disease 10:15–11:45 · Almeria Auditorium - Hall 2 — Isaac Garcia-Murillas, Marija Balic, Michael Alvarado
- Keynote lecture 2 12:15–12:45 · Almeria Auditorium - Hall 2
- Industry Satellite 25 13:00–14:30 · Oviedo Auditorium - Hall 5
- Industry Satellite 26 13:00–14:30 · Pamplona Auditorium - Hall 5
- Industry Satellite 27 13:00–14:30 · Salamanca Auditorium - Hall 5
- Industry Satellite 28 13:00–14:30 · Santander Auditorium - Hall 5
- Industry Satellite 19 13:00–14:30 · Cordoba Auditorium - Hall 6
- Industry Satellite 20 13:00–14:30 · Granada Auditorium - Hall 6
- Industry Satellite 21 13:00–14:30 · Leon Auditorium - Hall 6
- Industry Satellite 22 13:00–14:30 · Madrid Auditorium - Hall 6
- Industry Satellite 23 13:00–14:30 · Malaga Auditorium - Hall 3
- Industry Satellite 24 13:00–14:30 · Murcia Auditorium - Hall 3
- Expanding horizons in tumor-agnostic therapy: Beyond genotypes, AI-enabled insights, addressing resistance, and combination strategies 14:45–16:15 · Salamanca Auditorium - Hall 5 — Rodrigo Dienstmann, Jean-Pascal Machiels, Aya El-Helali
- Clinical approach to GEP NEN patients 14:45–16:15 · Murcia Auditorium - Hall 3 — Francesca Spada, Tessa Brabander, Detlef K. Bartsch, Louis De Mestier +1 more
- From immune surveillance and cancer evolution to better cancer immunotherapies 14:45–16:15 · Cadiz Auditorium - Hall 2 — Marcela Maus, Karl-Johan Malmberg, Yardena Samuels, Daniel Peeper
- Making significant strides in mesenchymal neoplasms 14:45–16:15 · Malaga Auditorium - Hall 3 — Sandra Strauss, Hans Gelderblom, Silvia Stacchiotti, Toshirou Nishida
- Management of penile cancer 14:45–16:00 · Cordoba Auditorium - Hall 6 — Nicholas A. Watkin, Karine Martins Da Trindade, Vedang Murthy
- Non-metastatic colon cancer: Well begun is half done 14:45–16:15 · Bilbao Auditorium - Hall 2 — Claire Gallois
- TP53 mutations and testing across haematological and solid cancers 14:45–15:30 · Oviedo Auditorium - Hall 5 — Arjan Diepstra
- You make the call: Adjuvant therapy decisions in molecularly defined endometrial cancer 14:45–16:00 · Madrid Auditorium - Hall 6 — Joyce F. Liu
- Beyond PD-L1: Biomarker-driven precision medicine in advanced head and neck cancers 16:30–18:00 · Granada Auditorium - Hall 6 — Kevin J. Harrington, Scott Bratman, Panagiota Oikonomopoulou
- SCLC in 2027: Navigating a rapidly evolving landscape 16:30–18:00 · Barcelona Auditorium - Hall 2 — Stephen V. Liu, Helena Linardou, Myung-Ju Ahn, Luis Paz-Ares
- Integrative models of supportive care and palliative care 16:30–17:45 · Madrid Auditorium - Hall 6 — Camilla Zimmermann, David Hui, Sebastien Moine
- The safety imperative: Toxicity across the expanding melanoma treatment landscape 16:30–18:00 · Leon Auditorium - Hall 6 — Mario Mandalà, Inge Marie Svane, Lucie Heinzerling, Olivier A. Michielin
- Grade II meningioma: A multidisciplinary case-based approach to optimise treatment 16:30–17:45 · Malaga Auditorium - Hall 3 — Felix Sahm
- Industry Satellite 32 18:30–20:00 · Murcia Auditorium - Hall 3
- Industry Satellite 36 18:30–20:00 · Santander Auditorium - Hall 5
- Industry Satellite 31 18:30–20:00 · Malaga Auditorium - Hall 3
- Industry Satellite 35 18:30–20:00 · Salamanca Auditorium - Hall 5
- Industry Satellite 34 18:30–20:00 · Pamplona Auditorium - Hall 5
- Industry Satellite 33 18:30–20:00 · Oviedo Auditorium - Hall 5
- Industry Satellite 29 18:30–20:00 · Cordoba Auditorium - Hall 6
- Industry Satellite 30 18:30–20:00 · Leon Auditorium - Hall 6
Day 3 — Sunday 19 September 2027
- Innovations redefining sarcoma care 08:30–10:00 · Malaga Auditorium - Hall 3 — Roberta Sanfilippo, Julien Vibert, Inga-Marie Schaefer, Javier Martin-Broto
- What to do after ADC/IO combination therapy in advanced urothelial cancer 08:30–10:00 · Barcelona Auditorium - Hall 2 — Jacqueline T. Brown, Xiaojie Bian, Yohann Loriot
- Unresectable NSCLC: Consolidation approaches and patient perspective 08:30–09:45 · Leon Auditorium - Hall 6 — Clarissa Maria De Cerqueira Mathias, Alona Zer, Yi-Long Wu, Rafal Dziadziuszko
- RAS-targeted therapies: From molecular understanding to clinical application 08:30–10:00 · Granada Auditorium - Hall 6 — Sandra Misale, Andrew Aguirre
- Regulatory challenges and innovation to support cell and gene therapy development 08:30–09:15 · Madrid Auditorium - Hall 6 — Leila Amini
- Across the skin cancers: Updates, resistance prediction, and trial innovation 08:30–10:00 · Cadiz Auditorium - Hall 2 — Alexander M. Menzies, Ines E. Pires da Silva
- From cancer risk to clinical care: A multidisciplinary approach 08:30–09:45 · Murcia Auditorium - Hall 3 — Judy E. Garber, Gabriella Pravettoni, Clare A. Turnbull, Sacha J. Howell
- How to treat diffuse IDH-mutant gliomas in 2027 10:15–11:00 · Salamanca Auditorium - Hall 5 — Marjolein Geurts, Evanthia Galanis
- Cancer across the age spectrum 10:15–11:45 · Murcia Auditorium - Hall 3 — Hemant Malhotra, Ravindran Kanesvaran, Winette T. Van der Graaf, Etienne G. Brain
- Treatment of advanced gastro-esophageal cancer 10:15–11:45 · Barcelona Auditorium - Hall 2 — Kohei Shitara, Josep Tabernero, Nadia Haj Mohammad
- Totality of evidence in phase I study: How much is enough for optimal decision 10:15–11:00 · Granada Auditorium - Hall 6 — Hui Gan, Do-Youn Oh
- T-cell engagers in haematology and oncology: Mode of action and resistance 10:15–11:45 · Oviedo Auditorium - Hall 5 — Martin Hutchings, Marion Subklewe, Gloria Iacoboni
- Emerging trends and new therapies in metastatic prostate cancer 10:15–11:45 · Burgos Auditorium - Hall 2 — Alice Bernard-Tessier, Kim Nguyen Chi
- Multidisciplinary management of patients with stage IV NSCLC and ILD 10:15–11:30 · Cordoba Auditorium - Hall 6 — Thomas Newsom-Davis
- Keynote lecture 3 12:15–12:45 · Almeria Auditorium - Hall 2 — Johann S. De Bono
- Industry Satellite 37 13:00–14:30 · Cordoba Auditorium - Hall 6
- Industry Satellite 38 13:00–14:30 · Granada Auditorium - Hall 6
- Industry Satellite 39 13:00–14:30 · Leon Auditorium - Hall 6
- Industry Satellite 40 13:00–14:30 · Madrid Auditorium - Hall 6
- Industry Satellite 46 13:00–14:30 · Santander Auditorium - Hall 5
- Industry Satellite 45 13:00–14:30 · Salamanca Auditorium - Hall 5
- Industry Satellite 44 13:00–14:30 · Pamplona Auditorium - Hall 5
- Industry Satellite 43 13:00–14:30 · Oviedo Auditorium - Hall 5
- Industry Satellite 42 13:00–14:30 · Murcia Auditorium - Hall 3
- Industry Satellite 41 13:00–14:30 · Malaga Auditorium - Hall 3
- Opportunities for optimisation strategies of locoregional therapy for postmenopausal women with early breast cancer 14:45–16:00 · Bilbao Auditorium - Hall 2
- Novel cancer treatments, novel toxicities and novel supportive care approaches 14:45–16:15 · Murcia Auditorium - Hall 3 — Alexander Lyon
- Promising biomarker-based therapies in NENs 14:45–16:15 · Oviedo Auditorium - Hall 5 — Margot Tesselaar, Mauro Cives, Mairead G. McNamara, Maribel Del Olmo
- Shaping early-stage NSCLC through systemic therapy 14:45–16:15 · Barcelona Auditorium - Hall 2 — Noemi Reguart, Ben Solomon, Elaine Shum, Raphael S. Werner +1 more
- The utility of ESMO Tumor-Agnostic Classifier and Screener (ETAC-S): Three years later 14:45–15:30 · Pamplona Auditorium - Hall 5 — Lillian L. Siu, Christoph Benedikt Westphalen
- Toward risk adaptive strategies in muscle-invasive bladder cancer (MIBC) 14:45–16:15 · Leon Auditorium - Hall 6 — Michiel S. Van der Heijden, Christof Vulsteke, Winette T. Van der Graaf
- Advances in liquid biopsy: Hot things ongoing in the lab 14:45–15:30 · Madrid Auditorium - Hall 6 — Marzia Del Re
- Connected care: Enabling the patient journey with digital tools 16:30–18:00 · Cadiz Auditorium - Hall 2 — Ines Vaz-Luis, Maria Alice Franzoi, David P. Miller
- Special topics in breast cancer management 16:30–18:00 · Barcelona Auditorium - Hall 2 — Alistair Ring, Laura A. Huppert, Cristina Saura Manich, Kevin Punie +1 more
- Consequences of anticancer therapy for aging, immunity, and clonal hematopoiesis 16:30–18:00 · Malaga Auditorium - Hall 3 — Claudia Waskow, Simon Husby
- Carcinoid syndrome-associated NET 16:30–17:45 · Oviedo Auditorium - Hall 5 — Grigorios A. Kaltsas, Alia Munir, Francesco Panzuto, Juan Manuel Ramon O'Connor
- Redefining platinum-ineligible ovarian cancer: From dynamic risk to precision treatment sequencing 16:30–18:00 · Burgos Auditorium - Hall 2 — Kathleen N. Moore, Frederik Marmé
- Industry Satellite 49 18:30–20:00 · Malaga Auditorium - Hall 3
- Industry Satellite 51 18:30–20:00 · Oviedo Auditorium - Hall 5
- Industry Satellite 54 18:30–20:00 · Santander Auditorium - Hall 5
- Industry Satellite 50 18:30–20:00 · Murcia Auditorium - Hall 3
- Industry Satellite 47 18:30–20:00 · Cordoba Auditorium - Hall 6
- Industry Satellite 48 18:30–20:00 · Leon Auditorium - Hall 6
- Industry Satellite 52 18:30–20:00 · Pamplona Auditorium - Hall 5
- Industry Satellite 53 18:30–20:00 · Salamanca Auditorium - Hall 5
Day 4 — Monday 20 September 2027
- Navigating systemic therapy for early stage breast cancer 08:30–10:00 · Burgos Auditorium - Hall 2 — Ana C. Garrido-Castro, Marion Van Mackelenbergh, Valentina Guarneri
- Diagnostic and response assessment markers in Hodgkin lymphoma 08:30–10:00 · Salamanca Auditorium - Hall 5 — Sven Borchmann, Martina Sollini
- The 2027 continuum of care pathway in metastatic colorectal cancer 08:30–10:00 · Bilbao Auditorium - Hall 2 — Dominik Paul Modest, Erika B. Ruiz-García, Aparna Parikh, Isacco Montroni
- Individualisation of treatment for locally advanced cervical cancer 08:30–09:15 · Murcia Auditorium - Hall 3 — Angelica N. Rodrigues
- Theranostics: When the biomarker is the therapy - Building programs from first-in-human to routine care 08:30–10:00 · Cordoba Auditorium - Hall 6 — Miguel Quintela-Fandino, Désirée Deandreis
- Innovative cell therapy in GI cancer 08:30–09:15 · Malaga Auditorium - Hall 3 — John B. Haanen, Changsong Qi
- How do we best incorporate ADCs into sequenced therapy for HER2 non-amplified breast cancer? 10:15–11:45 · Almeria Auditorium - Hall 2 — Hope S. Rugo, Jian Zhang, Sara A. Hurvitz
- How AI and digital twins are reinventing oncology clinical trials 10:15–11:45 · Cadiz Auditorium - Hall 2 — Paul A. Harris
- Emerging concepts and technologies to harness CNS cancer 10:15–11:45 · Murcia Auditorium - Hall 3
- Optimising multidisciplinary treatment in rare head and neck cancers 10:15–11:30 · Pamplona Auditorium - Hall 5 — Samantha O. Hasenleithner, Bhumsuk Keam
- Consolidative therapy in advanced RCC 10:15–11:30 · Cordoba Auditorium - Hall 6 — Christian K. Kollmannsberger
- Rectal cancer: When less is more and more is better? 10:15–11:00 · Leon Auditorium - Hall 6 — Ralf Dieter Hofheinz
- Improving the outcome of patients with large B-cell lymphoma 10:15–11:45 · Santander Auditorium - Hall 5 — Jason Westin, Sirpa Leppä
- What is the role of surgery in testis cancer in 2027? 10:15–11:00 · Granada Auditorium - Hall 6 — Patrizia Giannatempo
- Keynote lecture 4 12:15–12:45 · Almeria Auditorium - Hall 2
- Industry Satellite 60 13:00–14:30 · Pamplona Auditorium - Hall 5
- Industry Satellite 61 13:00–14:30 · Salamanca Auditorium - Hall 5
- Industry Satellite 58 13:00–14:30 · Murcia Auditorium - Hall 3
- Industry Satellite 59 13:00–14:30 · Oviedo Auditorium - Hall 5
- Industry Satellite 62 13:00–14:30 · Santander Auditorium - Hall 5
- Industry Satellite 55 13:00–14:30 · Cordoba Auditorium - Hall 6
- Industry Satellite 56 13:00–14:30 · Leon Auditorium - Hall 6
- Industry Satellite 57 13:00–14:30 · Malaga Auditorium - Hall 3
- Best endocrine management strategies of HR+/HER2 non-amplified MBC: Sequencing therapy in a rapidly changing treatment landscape 14:45–16:15 · Bilbao Auditorium - Hall 2 — Carlos H. Barrios, Komal Jhaveri, Veronique C. Dieras
- Personalisation of immunotherapy in NSCLC 14:45–16:15 · Almeria Auditorium - Hall 2 — Solange Peters, David Barbie, Nikolaj Frost
- Theranostic application of nuclear medicine in neuroendocrine and endocrine tumors: New insights 14:45–15:30 · Pamplona Auditorium - Hall 5 — Jaydira Del Rivero
- Neoadjuvant melanoma: Controversies and clinical dilemmas 14:45–16:00 · Leon Auditorium - Hall 6 — Alexander M. Menzies, Roger Olofsson Bagge, Sapna P. Patel
- Management of thymic malignancies: Current standards and novel therapies 14:45–15:30 · Malaga Auditorium - Hall 3 — Nicolas Girard, Erica Pietroluongo
- Redefining curative intent in gastroesophageal cancer 16:30–18:00 · Burgos Auditorium - Hall 2 — Hanneke Van Laarhoven, Filippo Pietrantonio, Beate Rau, Winta Mehtsun
- Cancer screening in transition: AI, risk stratification and MCED 16:30–18:00 · Granada Auditorium - Hall 6 — Anssi Auvinen, Fredrik Strand, Trevor Pugh
- Maintenance chemotherapy in advanced sarcoma: Who benefits and when? 16:30–17:15 · Malaga Auditorium - Hall 3 — Aisha Miah, Herbert Ho Fung Loong
- Incorporation of HIF inhibition across the spectrum of renal cell carcinoma (RCC) 16:30–18:00 · Bilbao Auditorium - Hall 2 — Manuela Schmidinger, Scott M. Haake, David F. McDermott, Gabriel G. Malouf
- Industry Satellite 64 18:30–20:00 · Pamplona Auditorium - Hall 5
- Industry Satellite 63 18:30–20:00 · Oviedo Auditorium - Hall 5
- Industry Satellite 65 18:30–20:00 · Salamanca Auditorium - Hall 5
- Industry Satellite 66 18:30–20:00 · Santander Auditorium - Hall 5
Day 5 — Tuesday 21 September 2027
- Scientific Congress Highlights 1 09:00–13:00 · Almeria Auditorium - Hall 2 — Hemant Malhotra, Ingrid Glimelius, Anna Sophie Berghoff, Fernando C. Maluf +4 more
- Scientific Congress Highlights 2 09:00–12:40 · Barcelona Auditorium - Hall 2 — Anne Letsch, Suzette Delaloge, Andrea Riccardo Filippi, Anna Koumarianou +3 more
Who is organising and sponsoring ESMO Congress?
Organiser (1)
European Society for Medical Oncology (ESMO)
Source: the published agenda. See how B2DB compiles its records.